Interleukin 6 inhibition: new possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases

Interleukin 6 inhibition: new possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases

Bibliographic Details
Main Authors:	E L Nasonov, E N Aleksandrova, A S Avdeeva, E Yu Panasyuk
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2013-11-01
Series:	Научно-практическая ревматология
Online Access:	https://rsp.mediar-press.net/rsp/article/view/1155

Similar Items

NEW POSSIBILITIES OF PHARMACOTHERAPY FOR IMMUNOINFLAMMATORY RHEUMATIC DISEASES: A FOCUS ON INHIBITORS OF INTERLEUKIN-17
by: E. L. Nasonov
Published: (2017-03-01)

New areas of the pharmacotherapy of rheumatic diseases are inhibition of interleukin-6 and interleukin-17
by: Evgeny Lvovich Nasonov
Published: (2013-10-01)

IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE
by: E. L. Nasonov, et al.
Published: (2019-09-01)

Clinical significance of antiDFS70 in immunoinflammatory rheumatic diseases (review)
by: T. A. Panafidina, et al.
Published: (2023-03-01)

Janus kinase inhibitors in immunoinflammatory rheumatic diseases
by: Evgeny L. Nasonov
Published: (2022-06-01)

IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
by: E. L. Nasonov, et al.
Published: (2019-09-01)

DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2017-04-01)

Shared features of pathogenetic aspects, autoimmunity and pharmacotherapy in coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases
by: K. S. Rutskaya-Moroshan, et al.
Published: (2022-10-01)

Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19
by: E. L. Nasonov, et al.
Published: (2022-05-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

Pathogenetic value of cell infiltrate in immunoinflammatory rheumatic diseases
by: M. Z. Saidov
Published: (2021-12-01)

New possibilities of movalis administration in rheumatic diseases
by: E. S. Tsvetkova, et al.
Published: (2003-08-01)

The role of autoantibodies in the early diagnosis of systemic immunoinflammatory rheumatic diseases
by: L. P. Ananyeva
Published: (2019-03-01)

DAMP-mediated inflammation and regulated cell death in immunoinflammatory rheumatic diseases
by: M. Z. Saidov
Published: (2023-02-01)

BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2020-06-01)

Immunoinflammatory rheumatic diseases: the role of the perception of the disease and coping with it in the psychological adaptation of the patient
by: I. N. Abrosimov, et al.
Published: (2022-12-01)

Sterile inflammation, cross-presentation, autophagy and adaptive immunity in immunoinflammatory rheumatic diseases
by: M. Z. Saidov
Published: (2024-04-01)

Predisposing role of childhood mental trauma in immunoinflammatory rheumatic diseases and mental disorders
by: S. A. Alekseeva
Published: (2022-09-01)

Use of Janus kinase inhibitors in the treatment of immunoinflammatory rheumatic diseases: safety issues
by: B. S. Belov, et al.
Published: (2021-03-01)

Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)
by: A. N. Kulikov, et al.
Published: (2022-02-01)

Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
by: E. L. Nasonov, et al.
Published: (2022-05-01)

New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
by: E. L. Nasonov, et al.
Published: (2021-10-01)

POSSIBILITIES OF USING LEFLUNOMIDE IN RHEUMATIC DISEASES
by: E V Igolkina, et al.
Published: (2011-03-01)

New possibilities of pharmacotherapy for systemic lupus erythematosus: A place of belimumab
by: E. L. Nasonov
Published: (2014-12-01)

Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
by: E. L. Nasonov, et al.
Published: (2021-12-01)

Innovative technologies in the laboratory diagnosis of rheumatic diseases
by: Elena Nikolayevna Aleksandrova, et al.
Published: (2010-04-01)

AUTOIMMUNE RHEUMATIC DISEASES: RESULTS AND PROSPECTS FOR RESEARCHES
by: E. L. Nasonov, et al.
Published: (2015-09-01)

B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)
by: E. L. Nasonov, et al.
Published: (2021-09-01)

Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders
by: T. A. Lisitsyna, et al.
Published: (2019-07-01)

MAST CELLS ARE KEY PARTICIPANTS IN THE PATHOGENESIS OF IMMUNOINFLAMMATORY DISEASES
by: E. O. Baglay, et al.
Published: (2015-04-01)

IMPACT OF THERAPY WITH BIOLOGICAL AGENTS ON B-LYMPHOCYTE SUBPOPULATIONS IN RHEUMATIC DISEASES: NEW EVIDENCE
by: E. V. Suponitskaya, et al.
Published: (2015-03-01)

INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES
by: Evgeny Lvovich Nasonov, et al.
Published: (2013-12-01)

EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II)
by: E. L. Nasonov, et al.
Published: (2020-04-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS
by: E. L. Nasonov
Published: (2017-09-01)

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
by: E. L. Nasonov, et al.
Published: (2020-02-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Clinical significance of collchicine in pharmacotherapy of cardiovascular pathology in patients with hyperuricemia in rheumatic diseases
by: L. E. Sivordova, et al.
Published: (2021-12-01)

CURRENT APPROACHES TO THE LABORATORY DIAGNOSIS OF RHEUMATIC DISEASES: ROLE OF MOLECULAR AND CELLULAR BIOMARKERS
by: E. N. Aleksandrova, et al.
Published: (2016-07-01)

New possibilities of infliximab administration in chronic inflammatory rheumatic diseases
by: A. I. Dubikov, et al.
Published: (2005-04-01)